Where Will Madrigal Pharmaceuticals Be in 3 Years?
Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is.
By mid-2027, its shareholders will probably be richer than they are today. But beyond that time point, all bets are off, and in fact, it's very possible for things to start getting more difficult for Madrigal a bit sooner. Here's what could happen and why.
As of today, there's one big reason why Madrigal should be seeing revenue flow to its top line -- and eventually earnings -- over the coming three years. Its medicine, Rezdiffra, is the only approved treatment for the liver disease called metabolic-associated steatohepatitis (MASH, formerly known as NASH).
Source Fool.com
